Anti-KCNK9 (TASK-3) antibody, Mouse monoclonal

Monoclonal Anti- KCNK9 (TASK-3), Clone KCN-75, (mouse IgG2b isotype) is derived from the KCN-75 hybridoma produced by the fusion of mouse myeloma cells (NS1) and splenocytes from BALB/c mice immunized with a synthetic peptide. Potassium two pore domain channel subfamily K member 9 (KCNK9) gene has been localized to the chromosomal region 8q24.

The gene KCNK9 (potassium two pore domain channel subfamily K member 9), also referred to as TWIK-related acid sensitive K(⁺) channel-3 (TASK-3), encodes a new member of the K2P (two pore domain K⁺ channel) family of proteins. It is found to be expressed in several rat tissues, such as brain, kidney, liver, lung, colon, stomach, spleen, testis, and skeletal muscle. It is also expressed to a lesser extent in heart and small intestine. All the potassium channels contain a conserved P domain that is involved in providing K⁺ selectivity and two, four, or six transmembrane segments.

synthetic peptide corresponding to amino acids 360-374 in the C-terminus of human KCNK9.

Anti-KCNK9 (TASK-3) antibody, Mouse monoclonal has been used in:

• immunoblotting
• immunohistochemistry
• immunocytochemistry

Potassium two pore domain channel subfamily K member 9 (KCNK9) is expressed in carcinomas including breast, lung, colon as well as in metastatic prostate. In 10% of breast cancer patients this gene is amplified, and in 44% the protein is overexpressed.

The gene KCNK9 (potassium two pore domain channel subfamily K member 9) encodes a tandem pore domain potassium channel that dimerizes to form a K⁺-selective pore. It is highly sensitive to change in pH and is involved in background leak potassium currents found in many cell types. The channel increases the hypoxia tolerance of malignantly transformed cells and facilitates its proliferation and/or survival. It may serve as a potential target for cancer therapies. Mutations in this gene can cause defects in the neuronal migration and have been associated with Birk Barel mental retardation dysmorphism syndrome. This oncogenic potassium channel is found to be expressed in epithelial ovarian cancer and patients with increased expression of this protein have better survival rates.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.